CRC with reduced CDX2 expression is associated with an increased likelihood of aggressive features such as advanced stage, poor differentiation, vascular invasion, BRAF mutation, and the CpG island methylator phenotype (CIMP) (81). Here, BRAF is linked to colorectal carcinoma.